Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2135 SEK | -1.39% | -39.35% | -97.86% |
04-22 | Transcript : Xbrane Biopharma AB - Special Call | |
03-18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
Sales 2024 * | 344M 31.41M 42.94M | Sales 2025 * | 680M 62.18M 85.02M | Capitalization | 327M 29.85M 40.81M |
---|---|---|---|---|---|
Net income 2024 * | -101M -9.23M -12.62M | Net income 2025 * | 104M 9.51M 13M | EV / Sales 2024 * | 0.55 x |
Net cash position 2024 * | 138M 12.65M 17.3M | Net Debt 2025 * | 116M 10.58M 14.47M | EV / Sales 2025 * | 0.65 x |
P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-
| Employees | 93 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
Latest transcript on Xbrane Biopharma AB
1 day | -1.39% | ||
1 week | -39.35% | ||
Current month | -29.19% | ||
1 month | -26.38% | ||
3 months | -86.57% | ||
6 months | -98.92% | ||
Current year | -97.86% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.2135 | -1.39% | 11,591,000 |
24-04-25 | 0.2165 | +4.09% | 37,415,150 |
24-04-24 | 0.208 | -3.48% | 49,579,610 |
24-04-23 | 0.2155 | -8.30% | 64,018,490 |
24-04-22 | 0.235 | -33.24% | 198,129,300 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.86% | 29.78M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XBRANE Stock